Dornase alfa
Dornase alfa is a clinically significant recombinant human deoxyribonuclease I (rhDNAse) that possesses selective DNA cleaving activity. When administered into the pleural cavity, it effectively catalyzes the degradation of extracellular DNA in airway secretions, leading to a reduction in their viscosity. This facilitates the clearing of mucus from the airways and potentially enhances overall pulmonary function.
Overview[edit]
Dornase alfa is a prime example of how biotechnological advancements can be applied in therapeutic settings. Its mechanism of action targets the thick mucus often seen in certain respiratory conditions by breaking down extracellular DNA, a primary contributor to mucus viscosity.
Mechanism of Action[edit]
Upon intrapleural administration, dornase alfa specifically targets and cleaves extracellular DNA strands present in the airway secretions. As DNA contributes to the thick and sticky nature of the mucus, its degradation by dornase alfa results in a more fluid and less viscous mucus, facilitating its clearance from the respiratory tract.
Therapeutic Benefits[edit]
- Mucus Clearance: By reducing the viscosity of airway secretions, dornase alfa promotes more efficient mucus clearance.
- Improved Pulmonary Function: Regular clearing of the airways may lead to improved lung function over time.
- Reduced Respiratory Complications: The effective management of mucus can lead to fewer pulmonary complications, such as infections and airway obstructions.
Clinical Uses[edit]
Dornase alfa is primarily utilized in the management of patients with conditions characterized by thickened mucus secretions in the airways, particularly in diseases like Cystic Fibrosis. By improving mucus clearance, the therapy can lead to better respiratory outcomes and overall quality of life for patients.
Side Effects and Precautions[edit]
As with any therapeutic agent, dornase alfa may have potential side effects. It's essential for patients to be monitored regularly and to report any unusual symptoms to their healthcare provider.
Research and Development[edit]
The development of dornase alfa represents the intersection of molecular biology and clinical therapeutics. Its creation was made possible through advanced recombinant DNA techniques.
See Also[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
- Budget GLP-1 shots
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian